ArticleACS nano2018
Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis.
Article in ACS nano, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Prognostic Value of Platelet to Lymphocyte Ratio in Sepsis: A Systematic Review and Meta-analysis.BioMed research international · 2022Pooled it
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- Recent advances in the biosensing platforms for sepsis diagnosis.RSC advances · 2026Review
- Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.Nature communications · 2025Article
- Transforming cytokine diagnostics: AI, multiplexing, and point-of-care biosensing technologies.Mikrochimica acta · 2025Review
- Current advances in multi-strategy collaborative sensitization for self-powered electrochemical biosensors and their applications in disease biomarker detection.Mikrochimica acta · 2025Review
- Article
- Harnessing artificial intelligence in sepsis care: advances in early detection, personalized treatment, and real-time monitoring.Frontiers in medicine · 2024Review
- Article
- An electrochemical paper-based hydrogel immunosensor to monitor serum cytokine for predicting the severity of COVID-19 patients.Biosensors & bioelectronics · 2023Article
- Fast Track Diagnostic Tools for Clinical Management of Sepsis: Paradigm Shift from Conventional to Advanced Methods.Diagnostics (Basel, Switzerland) · 2023Review
- Assessment of Immune Status Using Inexpensive Cytokines: A Literature Review and Learning Approaches.Sensors (Basel, Switzerland) · 2022Review
- Review
- Lateral Flow Immunoassay Reader Technologies for Quantitative Point-of-Care Testing.Sensors (Basel, Switzerland) · 2022Review
- Electrochemiluminescence in paired signal electrode (ECLipse) enables modular and scalable biosensing.Science advances · 2022Article
- Highly Sensitive Plasmonic Waveguide Biosensor Based on Phase Singularity-Enhanced Goos-Hänchen Shift.Biosensors · 2022Article
- Ultrafast Electrothermal Flow-Enhanced Magneto Biosensor for Highly Sensitive Protein Detection in Whole Blood.Angewandte Chemie (International ed. in English) · 2022Article
- Review
- Wave-shaped microfluidic chip assisted point-of-care testing for accurate and rapid diagnosis of infections.Military Medical Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Sepsis is an often fatal condition that arises when the immune response to an infection causes widespread systemic organ injury. A critical unmet need in combating sepsis is the lack of accurate early biomarkers that produce actionable results in busy clinical settings. Here, we report the development of a point-of-care platform for rapid sepsis detection. Termed IBS (integrated biosensor for sepsis), our approach leverages (i) the pathophysiological role of cytokine interleukin-3 (IL-3) in early sepsis and (ii) a hybrid magneto-electrochemical sensor for IL-3 detection. The developed platform produces test results within 1 h from native blood samples and detects IL-3 at a sensitivity of <10 pg/mL; this performance is >5-times faster and >10-times more sensitive than conventional enzyme-linked immunoadsorbent assays, the current gold standard. Using clinical samples, we show that elevated plasma IL-3 levels are associated with high organ failure rate and thus greater risk of mortality, confirming the potential of IL-3 as a sepsis diagnostic biomarker. With further system development ( e. g., full automation, data security measures) and rigorous validation studies, the compact and fast IBS could be a practical clinical tool for timely diagnosis and proactive treatment of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.